News from impel neuropharma A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Jan 20, 2021, 08:00 ET Impel NeuroPharma Announces U.S. Food & Drug Administration Acceptance Of New Drug Application For INP104 For The Acute Treatment Of Migraine

Impel NeuroPharma, a late-stage biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review...

Nov 09, 2020, 10:00 ET Impel Neuropharma Announces FDA Submission Of New Drug Application For INP104 For The Acute Treatment Of Migraine

Impel NeuroPharma, a late-stage biopharmaceutical company, today announced that it has submitted a New Drug Application (NDA) for INP104...

Oct 08, 2020, 08:00 ET Impel NeuroPharma Presents Data From Pivotal Phase 3 Registration Study Of INP104 For The Treatment Of Acute Migraine At 2020 Migraine Trust Virtual Symposium

Impel NeuroPharma, a late-stage biopharmaceutical company focused on the development and commercialization of transformative therapies for patients...

Jun 30, 2020, 13:10 ET Impel NeuroPharma Announces Publication of Positive Results of SNAP 101 Study for INP105 for the Treatment of Acute Agitation in The Journal of Clinical Psychiatry

Impel NeuroPharma, a late-stage biopharmaceutical company focused on the development and commercialization of transformative therapies for patients...

Jun 15, 2020, 07:30 ET Impel NeuroPharma Presents Data From INP104 Clinical Program In Acute Migraine At The 2020 American Headache Society (AHS) Virtual Annual Scientific Meeting

Impel NeuroPharma, a late-stage biopharmaceutical company focused on the development and commercialization of transformative therapies for patients...

Jun 10, 2020, 10:00 ET Impel NeuroPharma Announces Primary Objectives Met In Pivotal Phase 3 Registration Study Of INP104 For The Treatment Of Acute Migraine

Impel NeuroPharma, a late-stage biopharmaceutical company focused on the development and commercialization of transformative therapies for patients...

May 05, 2020, 08:00 ET Impel NeuroPharma Announces Leadership Transition, Chairman Adrian Adams' Role Expanded To Chairman And CEO

Impel NeuroPharma, a late-stage biopharmaceutical company focused on the development and commercialization of transformative therapies for patients...

Jan 16, 2020, 11:40 ET Impel NeuroPharma Announces Appointment of Sheena K. Aurora, MD, As Vice President of Medical Affairs - Migraine Franchise

Impel NeuroPharma, a late-stage biopharmaceutical company focused on the development and commercialization of transformative therapies for patients...

Jan 09, 2020, 16:01 ET Impel NeuroPharma Announces Appointment Of Adrian Adams As Chairman Of The Board Of Directors

Impel NeuroPharma, a late-stage biopharmaceutical company focused on the development and commercialization of transformative therapies for patients...

Nov 20, 2019, 11:49 ET Impel NeuroPharma Announces Publication Of Narrative Review In The Journal Headache Supporting Need For Novel Formulations Of Dihydroergotamine (DHE) In Addressing Acute Treatment Of Migraine

Impel NeuroPharma, a late-stage biopharmaceutical company focused on the development and commercialization of transformative therapies for patients...

Oct 17, 2019, 12:45 ET Impel NeuroPharma Announces Appointment Of Diane Wilfong To Board Of Directors

Impel NeuroPharma, a late-stage biopharmaceutical company focused on the development and commercialization of transformative therapies for patients...

Sep 05, 2019, 13:34 ET Impel NeuroPharma to Present Data From INP104 Clinical Program at the 19th Congress of the International Headache Society

Impel NeuroPharma, a late-stage biopharmaceutical company focused on the development and commercialization of transformative therapies for patients...

Sep 03, 2019, 13:12 ET Impel NeuroPharma Announces Last Patient Enrolled In Phase 3 Trial Evaluating INP104 For The Treatment Of Acute Migraine

Impel NeuroPharma, a late-stage biopharmaceutical company focused on the development and commercialization of transformative therapies for patients...

Jul 10, 2019, 15:26 ET Impel NeuroPharma to Present Data From INP104 Clinical Program at the 61st Annual Scientific Meeting of the American Headache Society

Impel NeuroPharma, a late-stage biopharmaceutical company focused on the development and commercialization of transformative therapies for patients...

Jun 26, 2019, 08:00 ET Impel NeuroPharma Appoints John Leaman as Chief Financial Officer

Impel NeuroPharma, a late-stage biopharmaceutical company focused on the development and commercialization of transformative therapies for patients...

May 17, 2019, 12:20 ET Impel Neuropharma to Present Data at 2019 American Psychiatric Association (APA) Annual Meeting

Impel NeuroPharma, a late-stage biopharmaceutical company focused on the development and commercialization of transformative therapies that unlock...

Apr 30, 2019, 10:32 ET Impel NeuroPharma To Present Data Highlighting Late-Stage Central Nervous System Pipeline At 2019 American Academy Of Neurology Meeting

Impel NeuroPharma, a late-stage biopharmaceutical company focused on the development and commercialization of transformative therapeutics for...

Feb 19, 2019, 08:00 ET Impel NeuroPharma Appoints Jennifer L. Berman As Vice President Of Marketing

Impel NeuroPharma, a Seattle-based, privately-held biotechnology company focused on therapies for the treatment of central nervous system (CNS)...

Jan 06, 2019, 10:00 ET Impel Neuropharma Announces Positive Phase 1 Trial For INP105 For The Treatment Of Acute Agitation In Bipolar I Disorder And Schizophrenia

Impel NeuroPharma, a Seattle-based, privately-held biopharmaceutical company focused on innovative therapies for the treatment of central nervous...

Nov 07, 2018, 08:00 ET Impel NeuroPharma Appoints Ellen A. Lubman As Chief Business Officer

Impel NeuroPharma, a Seattle-based, privately-held biotechnology company focused on developing therapies for the treatment of central nervous system...

Aug 29, 2018, 08:00 ET Impel NeuroPharma Annouces First Subject Dosed In Phase 1 Trial Evaluating INP105 For The Treatment Of Acute Agitation In Bipolar I Disorder And Schizophrenia

Impel NeuroPharma, a Seattle-based, privately-held biopharmaceutical company focused on therapies for the treatment of central nervous system (CNS)...

Aug 22, 2018, 08:00 ET Impel Neuropharma Announces First Patient Dosed In Phase 3 Trial Evaluating INP104 For The Treatment Of Acute Migraine Headache

Impel NeuroPharma, a Seattle-based, privately-held biopharmaceutical company focused on therapies for the treatment of central nervous system (CNS)...

Jul 16, 2018, 08:45 ET Impel NeuroPharma Strenthens Leadership Team With Appointment Of Lynn C. Gold As Senior Vice President Of Regulatory Affairs

Impel NeuroPharma, a Seattle-based, privately-held biotechnology company focused on therapies for the treatment of central nervous system (CNS)...

Jun 26, 2018, 12:00 ET Impel NeuroPharma To Present New Data On INP104 For Treatment Of Acute Migraine At 2018 Annual American Headache Society Meeting

Impel NeuroPharma, a Seattle-based, privately-held biotechnology company focused on therapies for the treatment of central nervous system (CNS)...

May 31, 2018, 08:00 ET Impel NeuroPharma Announces Initiation of Phase IIa Study of INP103 in Parkinson's Disease OFF Episodes

Impel NeuroPharma, a Seattle-based, privately-held biotechnology company focused on therapies for the treatment of central nervous system (CNS)...